Consensus is $513.16M. Crysvita revenue is expected to be towards the upper end of the range of $375M-$400M. This includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023. Dojolvi revenue is expected to be in the range of $75M-$80M. The company sees net cash used in operations less than $400M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
- RARE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ultragenyx to present GTX-102 Angelman syndrome program update
- Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Questions or Comments about the article? Write to editor@tipranks.com